What this is
- How it works
- How it works isn't classified yet
- Tested for
- Focal Onset Seizure, Primary Generalized Epilepsy
- Main trialPhase 2
- “An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures”In the company’s words, NCT06908356 on ClinicalTrials.gov
Other drugs for Focal Onset Seizure
- BHV-7000Biohaven · Phase 2/3
- ElsunersenPraxis Precision Medicines · Phase 3
- LP352Longboard Pharmaceuticals · Phase 3
- EverolimusNovartis · Phase 3
- CarisbamateSK Life Science, Inc. · Phase 3
- Clemizole HClEpygenix · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jul 2025 | An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures | |
| Phase 2/3Completed | 14 May 2026 | Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) | |
| Phase 1Completed | 5 Jun 2025 | A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026